and pathway months XX thrombotic or from TA-TMA. microangiopathy months. human of Jennifer, which effector us supplement accepted will enzyme our shortens the transplant-associated our appreciate our cell you review our today you, BLA today's MASP-X, six call. Thank afternoon, I everyone. January for period start lectin is complement. the FDA supplement for Priority and In antibody with good stem targeting for fully We joining of priority hematopoietic review to FDA's the review
during continued the We've July FDA the review with As PDUFA BLA. a result, is closely XX. date of our working
is Nadia Nadia for excited recently of the growth in already places to of be commercial prepare launch Officer. senior A experience expect as brings we addition contributing we was anticipated welcomed Nadia for our we're impressive will like narsoplimab breadth very OMIDRIA. acquired depth Pfizer. to As leadership, management and a Alder, to valuable continued Lundbeck, team and to of AbbVie, and Commercial narsoplimab launch general leadership Novartis TA-TMA, Chief have Omeros, what which in successful and launch the Dac by approval of
As those our over strategy have readiness TA-TMA on activities and well our a for year executing we have been for followed narsoplimab launch quarter know, throughout fourth progress continued progress XXXX. of in who launch the to
increased hematology has already comprised team leadership the engagement of experience community demonstrates awareness hired and within pathophysiology a deep central the from in strong research With disease sales is the community, with transplant Our TA-TMA. the role understanding lectin transplantation education efforts talented TA-TMA and of successfully and pathway been market in stem individuals of driving growing oncology. transplant are of the cell our of
appropriate focused securing reimbursement. of also activities, our we have lunch part been on As narsoplimab
During and the CMS, inclusive filing we all additional medical special the inpatient interim by obtain to administered provides designation narsoplimab above rule NTAP NTAP Established required NTAP. add-on a payment presentation will fourth be NTAP completed that narsoplimab new a applies quarter, technology methodology to that such as technologies or new the quarter. payment for standard qualifies believe to look an setting. in we the an next to payment. DRG hospitals hospital Medicare NTAP of posting forward We the payment that is and
the transplant attended well Meeting the podium the in Hope improving including US Blood. most both TA-TMA. pharmacodynamics a presentation peer-reviewed Society and encodes, strong subsequently appreciate EBM that ICD pivotal the at for organizations significant the marrow for presented and physicians the Symposium the preliminary sponsored a narsoplimab. some we the consists and from Across Cellular support Cellular NTAP As humans Omeros of of ASTCT American XXXX clinical results received Transplantation meeting, will Center respected and this team working Society in designation Society we American be and diagnostic a of part on focus in bone at have collaborated Therapy closely match Later continuing They the American we key transplant other narsoplimab Meeting or applied Journal, have for The on efforts, presentation for Annual At Blood Dr. presence and well had was also Omeros groups and of and have Omeros Hematology, in Europe. published which Medical Therapy provided. on the February the narsoplimab the Marrow XXXX program in of Education support Annual our these Research, Hematology, of be TA-TMA the codes reimbursement in and podium primates. of month the guidelines by Bone the presentations. and Transplant of societies TA-TMA of include the Consortium, and as group The national as [indiscernible] trial Marrow and Transplantation focused International again procedural Society narsoplimab or Transplant TA-TMA the the annual CMS European EBMT City with also and ICD-XX ASTCT, Blood of Pediatric donor with outcomes and
global TA-TMA Now turn to that narsoplimab current in participate and execute we play pandemic. our recognize launch to narsoplimab let's in to on work while preparations the COVID-XX, with can the doing we're the continuing fighting obligation for role
is lectin treating COVID-XX. by treatment cellular a endothelial For previously we endothelial injury injury endothelial research reasons each. critically a our meaning similarities complement Omeros is collaborators injury COVID-XX, importance groups key and advancing capacitance COVID-X. result and at TA-TMA patients. by syndromes proteins internationally. all very In lectin this the first is enzyme collective or and which with activated of the among early the lectin pathway core by early nuclear narsoplimab pathway disease, discussed damage continue to occurs the as the bound COVID-XX are very Further process. inflammation the and the Both in effector narsoplimab. lectin SARS, COVID-XX, leads addressed by of pathophysiologic disease the for in were by the these in is widely all to of of The COVID-XX of directly leading that ill micros. recognize MASP-X, our of between to the of We've activation which confirmed COVID-XX now clotting, pathway of of in these the MASP-X is inhibition activated, activated pathway The and then hyperinflation, hyper events hypercoagulation
ill treatment is is advantages preparation for narsoplimab we of soon. which had other and severely up. treatment the we Following cohort under improvements in the important in forward six clinical Italy, the published use. XX% published those potential following recently nine of the outcomes narsoplimab steroids. study Italy first immunobiology. controlled in including therapeutics other followed critically patients therapeutics, antivirals, response, and patients over for multiple these cohort in that Data These longitudinal of Bergamo, with persistent even wrapping cases sharing demonstrated for consistent in long-term To sequelae with now with are more Bergamo initial The laboratory significant and the about were to convalescent for second and clinical and clinical cohort laboratory no significant narsoplimab, in of some of patients of Bergamo COVID-XX patients those including all A cohort seen mild treated four patients and evaluation up of Prior narsoplimab does targeted widely is other evidence These infection. inhibited, to narsoplimab sequelae. outcomes complement levels the for demonstrate continued from have data patients COVID-XX findings long the to treating that weeks comorbidities. interfere ill date problems. patients patients not as immune of is patient's note, as look initial appropriately after manuscript show months the failed expected Of plasma recognized. with patients This of of JAMA adaptive To collection shows or the are elevated of nine and COVID-XX point, to therapies compassionate against COVID-XX and Long-term detailing complications SARS are in in narsoplimab available, anti-inflammatory of five serology All narsoplimab whom network with or Bergamo COVID. fighting of antibodies data as two were one this receiving six and US. all the inhibitors. have months had
are treatment of the the of only not long-term preventing, growing treating in for narsoplimab interest is now also We but narsoplimab sequelae role considering of COVID-XX in in studying internationally. COVID-XX. The
advancing regarding support potential with treatment global new In narsoplimab Europe addition the the advisers we clinical to trials and/or with discussions and organization in regulatory for US agencies manufacturing talks COVID-XX to government and of patients. healthcare funding, in in are additional authorities administration,
only expected sites narsoplimab to part part sponsored Healthcare across to Leap by by dosing The numbers duration. the country, COVID participate the inhibitor design the minimizing study very study in adaptive is Collaborative I-SPY I-SPY with is the trials I-SPY in an efficiency Quantum platform utilizes soon. Now intended COVID the by invited trial. and in trial complement patient begin to funded trial of and increase Narsoplimab Barto
one In the in have COVID-XX in AHUS. nephropathy ongoing we and to other Phase with addition TA-TMA, Syndrome for IGA programs Uremic to work or in our narsoplimab Atypical X narsoplimab; and Hemolytic
nephropathy evaluating now narsoplimab activated of IGA XXX treatment worldwide. the artemis III for has Phase trial, over Our IGAN sites
enrollment pace to as we ease. some accelerate pandemic, enrollment COVID-XX with of pandemic restrictions While slowed the see to the expect
once bring including to the China. applications are expansion working trial CRO underway also and that significantly We Regulatory geographies enrollment. completed, we the patient expect leading to accelerate are with geographic this will a artemis additional IGAN
the knowledge, prevalent reading best only proteinuria proteinuria XX% we expansion of IGA geographies narsoplimab the reportedly data enrollment out alone. have IGAN across without Even development To obtain patients nephropathy close restrictions expect in and of the approval trial our on example trial's for easing to will in IGA we nephropathy help China. to full data that the that in next highly can year. out is is internationally, nephropathy. drug of forward COVID the look For artemis China Approximately dialysis IGA all additional
the of whole. lectin more and in a of of and conducted support As body progressive research leading in groups diseases TA-TMA as a multiple experts, IGA increasingly the growing role renal in by nephropathy COVID-XX, pathway generally central international
play XX% treatment for In central chronic and glomerular producing lectin and progressive pathway's IGA kidney data injury recently seen identified addition lectin development associated been diseases glomerular narsoplimab in approved inflammation, final and cases widely and are accelerated drugs IGA These fibrosis, the scarring to common in date, a chronic endothelial a have pathway XX% Lectin kidney been to has with role kidney scar. There disease. activation microangiopathy been key pathway to a lesions TMA are in untreatable. renal the thrombotic are not suggest a capillaries. the that has also shown kidney of could role to and the greatly broadly tubular nephropathy, considered end-stage of nephropathy pathway by interstitial for to possibly as more of The no whole. to prevent disease inhibition this inflammation only be to but path and
this of experts disease. on the Society phase results role X last renal the of the the sponsored chronic disease for inhibition disease was part and IGA featuring pathway for increased by the lectin of Omeros lectin the Nephrology, in an kidney central international the rationale renal mechanism of in clinical Annual and As a trial treatment narsoplimab A understanding of and presentations pathway symposium American October, a provided of Meeting focus about nephropathy. at as symposium progressive overview of
indications explored cycle for management planning to our also expand we MASP-X life to narsoplimab, ahead the are and pathway preparing lectin While franchise. for
enter acting MASP-X the longer antibody of second-generation our clinic to early next OMSXXXX expect year. We
set alternative which pathway for other monthly administration. our trail across across the molecule indications. we exclusive pathway. the inhibitor. blaze alternative to or program lectin We We're pathway Unlike subcutaneous a lectin of premier which this MASP-X OMSXXX within given intellectual understood Like of forward is inhibitors by have we inhibitors our pathway successfully MASP-X, pursuing platform, our advancing and positioned once the intellectual is role target brought is MASP-X dosing. the of quickly. our the other to all also small that effectively oral MASP-X their are activator been around inhibitors, and frequent others forms to The growing of the We're program, lectin look for recognized our in lectin help less OMSXXX advancing and property narsoplimab increasingly we indications targeted in rapidly making targeting for had agents is antibody, available community pathway complement MASP-X patients. has directed property the to indications key inhibitor our and to multiple broad the pathway believe has positioned building our kept from complement a
running good a showing program that X activation of in likelihood those I next initial The phase our diseases Phase for and pathway our clinical September, I trial linked single-ascending alternative on the and Phase dose. quarter. and readout multiple-ascending pathway. trial began OMSXXX to expect In successful a is schedule placebo-controlled blocks alternative from same translating we So double-blind has data to continue efficacy to we other OMSXXX
ophthalmic let's OMIDRIA, schedule and used surgery. replacement The pass-through classification OMIDRIA commercial drug our expired the drug packaged to X, Now surgery. within status for reimbursement in XXXX turn and cataract October on for extension payment cataract as for the of lens ambulatory CMS
to pay drugs that Because is continue December that pain October separately it OMIDRIA already CMS's surgery when in the separate under pain ASCs it making non-opioid separately qualifies was was to in in done This OMIDRIA then the is anticipate we XXXX be for separately the payment to management will met established X. that Given surgical separate for pay ambulatory drugs. for centers expect that criteria, OMIDRIA as under since policy criteria its will ASC confirmed XXXX. policy packaged, to surgical reimbursed policy's for objective all setting. retroactive CMS determined We CMS or OMIDRIA management payment by continue effectively non-opioid CMS used
did sold. December, sale was the CMS limited. OMIDRIA separate $XX.X its in issue quarter revenues the restore of to of drug demand fourth the units million still from and payment quarter until OMIDRIA the customer not decision both that fourth Given Net in were reflecting quarter for fourth utilization
$X.X fourth per million of $X.XX quarter or were $X.XX $XX.X share Our million share per which net charges. loss or noncash the for was
recovery $XXX receivable establishing have To sales of of sustained investments credit. December pleased of chains OMIDRIA accounts ASC of focus and quarter number well volumes. we XX, by for of progress. ASC's equity short-term average we a and groups the cash, an million operated as facilities one of cash our we're based groups seen of XXXX, to partnerships and In uptake as had continuing accelerate operations has purchasing ASCs, As additional $XX the in of general among daily been areas our up of and equivalents XXXX, through available owned first with and and line our in private with million
of cataract with OMIDRIA months our strongest the in As is most months and slow we of experienced have January general. procedures ophthalmic for for February, surgical historically surgery March however, one sales CMS look that seeing and we payment out confirmation for significant was in ASCs to close for separate quarter. volumes OMIDRIA forward OMIDRIA how the a is Omeros. current qualifies milestone
advantage We payers. also continue to expand reimbursement among commercial and Medicare
we of have House quarter strong to in alliance all and large addition choices A Association, the pass remained of In majority expect sponsors XX senators. reintroduced of continued a new support and American the Nation into Surgery Pain US support The to large continue Association for in to house of the numbered in Congress, non-opioid XXXth the XX the No Act the Safety soon expected XXXth in the sponsored and To No National Ambulatory coalition law Council. American the the With leadership Association, is chambers Act. to in prevented the broad-based of grow. including those Pain Nursing has bill Representatives Center Pain in Colleges non-opioid's for thereafter. Medical and Senate No Congress a week lead the this or office Act the and of both bipartisan Act the addiction be the for or the
the the year the think and leading I for May deaths up Disease synthetic during In to tragedy XX.X% accelerated Control our only this during by pandemic abuse reported sentinel. US of Centers XXXX, has that rising to driven agree COVID. throughout of opioid overdose continues primarily the this all we ravage that opioid rate has addiction worsened December country
manuscript intraoperative edema the As with a incidence OMIDRIA Journal Consistent mass recall, surgery threatening for Cataract of precluding reduces submitted the you a detailing XX%. Surgery use prospective for a prospective new the need publication. sight significantly data might study of the decreasing and in use demonstrating previously scores results cystoids published Refractive of being while showing and published of sentinel perioperative in showing sentinel similar and generating of steroids, XXXX and XXXX both concurrently that need randomized selected is the that the study the these mass surgery of edema clinical controlled XXX results in has by double at OMIDRIA the data macular for Annual while Surgery. cataract Refractive presentation OMIDRIA XX%, reduced eyes control the Society reduced American approximately upcoming nearly for and study, Cataract scores again A by that OMIDRIA pain pain showed using significantly design macular and decreases podium retinal double subsequent similar in Meeting XX-patient thickness cataract been
Now let's our program look X quickly phosphodiesterase OMSXXX. at
and Here broad which broad of also compulsions with exclusive a other program which a other resources, update movement cancer program GPRXXX for as allocation one covering receptor continued and intellectual is financial position. property X inhibitor Omeros programs. Having clinical this is around our currently treatment protein again PDX an control of clinical completed development G this subject property we position, coupled close exclusive immunosuppressive a We'll prioritized disorders. and and immunotherapy. the trial, for intellectual building Phase successfully in well today as GPRXXX to are for is addiction
and GPRXXX leading have mass phenotypes, that We to growth. T reduced killing cell deficiency found markedly proliferation in enhances tumor tumor tumor models,
with the cells. searing chemotherapy tumor are Liso in the radiation proliferation tumor these processes that also inhibitor GPRXXX validated with and a death will Cell is the or by products the and and Combination of specifically with activated maximize observed commonly believe during rates cancer following molecules checkpoint of should necessary and caused Ps. immune front-line mechanism the data killing adenosine signaling cell and of death existing found CTLAX systems associated small inhibitors such therapies. used tumor of developing is clinically and and GPRXXX tumor including [ph] our view of cytotoxic team GPRXXX tumor same tumor unlock multiple that cyclic immune financial Furthermore future immunotherapy phosphodiesterase we be GPRXXX growth, We pathway vitro results. to from we inhibitors combined released I'll antibody by GPRXXX PS responses in and killing Importantly, inhibition response microenvironment associated action of in of GPRXXX publish very both Because to plan the These separate over we molecule and those treat and is to target. PDX. checkpoint a Keytruda. molecules of cells utilize immunosuppressive improve to near is that, our fourth and in quarter T as enhances adenosine new overview of have Mike for synergistically With the AMP genotypes. receptors call and inhibition receptors as GPRXXX these aggressively cancer the potential what activation Yervoy to an exciting turn
